PMS17 lonG-terM DeCreASe in Gout flAre rAteS ASSoCiAteD With effeCtive urAte loWerinG therAPy Kelton K. Medical Decision Modeling, Indianapolis, IN, USA OBJECTIVES: Previous clinical trials have demonstrated that gout patients who achieve the target serum urate acid (SUA) level ≤ 6 mg/dL with urate lowering therapy (ULT) experience a reduction in the frequency of gout flares over time. This finding has not been fully exploited in pharmacoeconomic models of ULTs that associate constant flare rates with SUA levels. The objective of this study was to quantify the long-term rate of decrease in flare frequency among subjects who achieved the target SUA level in the fEbuXostat/allopurinol Comparative Extension Long-term study (EXCEL). METHODS: The EXCEL trial reported the proportion of subjects experiencing ≥ 1 gout flare requiring treatment by two-month intervals. Binomial regression was used to fit Gompertz and Weibull survival models to the observations at least 6 months after baseline, pooled across treatment arms. Model fit was assessed by a chi-square test of the model deviance. RESULTS: The goodness of fit test for the Gompertz survival model indicated that the model provides an adequate fit to the data (model deviance = 14.14 with 15 degrees of freedom; p= .5146). However, the goodness of fit test for the Weibull survival model indicated an inadequate fit to the data (model deviance = 55.01 with 15 degrees of freedom; p< .0001). The maximum likelihood estimate of the shape parameter of the Gompertz survival model is -0.0906, where time is measured in months. CONCLUSIONS: The longterm (≥ 6 months after baseline) gout flare results reported in the EXCEL trial can be adequately modeled by a Gompertz survival model, which estimates that the gout flare rate decreased by 9.06% per month for subjects who achieved the target SUA level of ≤ 6 mg/dL. The results of this analysis may be useful for modeling the long-term clinical and economic outcomes of ULTs in patients with gout.
PMS18 uSe of Anti-oSteoPoroSiS MeDiCAtionS AnD frACture riSk AMonG elDerly PAtientS With enD-StAGe renAl DiSeASe: A retroSPeCtive Cohort StuDy
Lo P. 1 OBJECTIVES: Evidence supporting the use of anti-osteoporosis (AO) medications (AOMs) for preventing fracture among elderly patients with end-stage renal disease (ESRD) was scarce. This study evaluated the benefits of AOMs in fracture prevention for elderly patients with ESRD. METHODS: Using 1997-2008 Taiwan's National Health Insurance research database, we identified incident chronic dialysis patients with concomitant diagnosis of osteoporosis who had received AOMs during the year before dialysis between 1998 and 2007; the AOMs included salmon calcitonin, alendronate, zoledronate, raloxifene, and teriparatide. Following the inception of dialysis, patients who continued AOMs were categorized into AO treated cohort and those who ceased using AOMs were AO untreated cohort. Study outcomes were defined as hospitalizations due to hip or vertebral fracture during the follow-up period. RESULTS: We identified 490 patients receiving AOMs during the year before dialysis. The mean age of AO untreated cohort and AO treated cohort were 74.40 and 71.64. Fracture hazard risk (HR) in the AO treated cohort was not significantly lower than the AO untreated cohort, either unadjusted (HR = 1.02, 95%CI = 0.40-2.62, p = 0.96) or adjusted (HR = 0.92, 95%CI = 0.30-2.82, p = 0.89). Further analysis in female patients resulted in a similar finding. CONCLUSIONS: This study found that use of AOMs was not associated with a reduction of fracture risk in elderly chronically dialyzed patients.
retrospective medical chart-review of RA patients was conducted to collect deidentified data for those recently treated with a biologic as part of usual care. Physicians (rheumatologists) were screened for duration of practice (3-30yrs) and patient volume (incl. > 5 RA biologic patients/month) and recruited from a large panel to be geographically representative. Eligible patient charts (≥ 3) were randomly selected from a sample of patients visiting each center/practice during the screening period. ) were on their first biologic. The adalimumab group appeared to have a slightly higher disease burden and comorbidities. Factors influencing the observed patterns (including the choice of specific biologic for targeted patient profiles) may warrant further scrutiny to optimize therapeutic interventions and improve outcomes.
PMS14 effiCACy of tofACitinib in CoMbinAtion With MethotrexAte CoMPAreD to bioloGiCAl DMArDS in CoMbinAtion With MethotrexAte in rheuMAtoiD ArthritiS PAtientS With An inADeQuAte reSPonSe to MethotrexAte: overvieW of SySteMAtiC revieW
Reyes J. M. 1 , Rodriguez A. 2 1 Pfizer SAS, Bogota, Colombia, 2 Universidad Nacional, Bogota, Colombia OBJECTIVES: Tofacitinib is a new oral drug which has demonstrated efficacy and safety in pivotal clinical trials. This study sough to assess the efficacy of tofacitinib in combination with methotrexate compared with biological DMARDs in combination with methotrexate, in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate. METHODS: We performed an analysis of systematic review published in the last five years that assessed biological DMARDs (Adalimumab, certolizumab, infliximab, etanercept, golimumab, tocilizumab, rituximab and abatacept) or tofacitinib to treatment of RA after inadequate response to methotrexate. The search was realized in the database of Medline, EMBASE, Cochrane, LILACS, DARE and HTA. The data collection was realized by two researchers independently. Clinical trials that had been included in the systematic reviews were extracted and evaluated their methodological quality with checklist Cochrane. With mixed treatment comparison, the effectiveness between biological DMARDs and tofacitinib was compared using methotrexate as a common comparator. The outcomes considered in terms of effectiveness were improvement rates by ACR20, ACR50, ACR70 and HAQ criteria at 12 and 24 weeks. In order to evaluate the impact of heterogeneity, we performed analysis of sensibility and subgroups. RESULTS: 27 systematic reviews were included of which 30 clinical trials were assessed and analyzed. The indirect comparison showed that tofacitinib has similar efficacy in comparison to biological DMARDs in ACR20, ACR50, ACR70 and HAQ at 12 and 24 weeks. However, certolizumab displayed better response that tofacitinib in ACR20 at 12 weeks (OR 0.373 IC 95% 0.201 -0.615). The sensitivity and subgroup analyses by the design of clinical trials, years of disease and number of swollen joint showed consistent results. CONCLUSIONS: The mixed treatment comparison indicated that tofacitinib is similar in terms of efficacy than biological DMARDs in RA patients with an inadequate response to methotrexate.
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